J&J takes a $630M as­set hit on the books, shut­ter­ing PhI­Ib tri­als as its $1.75B RSV drug teeters on the brink

Al­most ex­act­ly 4 years af­ter J&J paid $1.75 bil­lion for a lit­tle biotech called Alios, one of the cen­tral drugs fea­tured in the deal ap­pears …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.